Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Insulin receptor substrate 2 plays a crucial role in β cells and the hypothalamus
Naoto Kubota, … , Takashi Kadowaki, Tetsuo Noda
Naoto Kubota, … , Takashi Kadowaki, Tetsuo Noda
Published October 1, 2004
Citation Information: J Clin Invest. 2004;114(7):917-927. https://doi.org/10.1172/JCI21484.
View: Text | PDF
Article Metabolism

Insulin receptor substrate 2 plays a crucial role in β cells and the hypothalamus

  • Text
  • PDF
Abstract

We previously demonstrated that insulin receptor substrate 2 (Irs2) KO mice develop diabetes associated with hepatic insulin resistance, lack of compensatory β cell hyperplasia, and leptin resistance. To more precisely determine the roles of Irs2 in β cells and the hypothalamus, we generated β cell–specific Irs2 KO and hypothalamus-specific Irs2 knockdown (βHT-IRS2) mice. Expression of Irs2 mRNA was reduced by approximately 90% in pancreatic islets and was markedly reduced in the arcuate nucleus of the hypothalamus. By contrast, Irs2 expression in liver, muscle, and adipose tissue of βHT-IRS2 mice was indistinguishable from that of control mice. The βHT-IRS2 mice displayed obesity and leptin resistance. At 4 weeks of age, the βHT-IRS2 mice showed normal insulin sensitivity, but at 8 and 12 weeks, they were insulin resistant with progressive obesity. Despite their normal insulin sensitivity at 8 weeks with caloric restriction, the βHT-IRS2 mice exhibited glucose intolerance and impaired glucose-induced insulin secretion. β Cell mass and β cell proliferation in the βHT-IRS2 mice were reduced significantly at 8 and 12 weeks but not at 10 days. Insulin secretion, normalized by cell number per islet, was significantly increased at high glucose concentrations in the βHT-IRS2 mice. We conclude that, in β cells and the hypothalamus, Irs2 is crucially involved in the regulation of β cell mass and leptin sensitivity.

Authors

Naoto Kubota, Yasuo Terauchi, Kazuyuki Tobe, Wataru Yano, Ryo Suzuki, Kohjiro Ueki, Iseki Takamoto, Hidemi Satoh, Toshiyuki Maki, Tetsuya Kubota, Masao Moroi, Miki Okada-Iwabu, Osamu Ezaki, Ryozo Nagai, Yoichi Ueta, Takashi Kadowaki, Tetsuo Noda

×

Figure 6

Options: View larger image (or click on image) Download as PowerPoint
β Cell mass and β cell proliferation were not reduced in βHT-IRS2 mice a...
β Cell mass and β cell proliferation were not reduced in βHT-IRS2 mice at 10 days. (A) Body weights of control and βHT-IRS2 mice. Values are means ± SE of data obtained from the analysis of control (black bar, n = 4) and βHT-IRS2 mice (white bar, n = 4). (B) Random blood glucose levels of control and βHT-IRS2 mice. Values are means ± SE of data obtained from the analysis of control (black bar, n = 4) and βHT-IRS2 mice (white bar, n = 4). (C) Histological analysis of pancreatic islets (left) and quantitation of β cell mass (right) in control and βHT-IRS2 mice at 10 days. Representative islets viewed on a computer monitor are shown. Results are shown as area of β cell mass. Values are means ± SE of data obtained from the analysis of control (black bar, n = 4) and βHT-IRS2 mice (white bar, n = 4). Original magnification, ×200. (D) BrdU incorporation into β cell nuclei of control and βHT-IRS2 mice. Results are shown as the percentage of cells that had incorporated BrdU. Values are means ± SE of data obtained from the analysis of control (black bar, number of islets = 67) and βHT-IRS2 mice (white bar, number of islets = 58). Original magnification, ×400 (upper panels); ×600 (lower panels). Arrowheads indicate cells that have incorporated BrdU.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts